Navigation Links
Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference

DURHAM, N.C.--(BUSINESS WIRE)--Jul 3, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L. Shaffer, Ph.D., President and CEO, will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Wednesday, July 11, 2007 at 11:00 am ET in New York City.

The webcast of the presentation will be available on Inspire's web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Contact

Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin
VP, Investor Relations and Corporate Communications
919-941-9777, ext. 219
or
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007 ext. 14


'"/>




Page: 1

Related medicine technology :

1. Inspire Announces Presentations at Two European Scientific Conferences
2. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

Post Your Comments:
(Date:11/6/2009)...,, OAKLAND, Calif., Nov. 6 Kais... Hospitals (KFHP/H), and their subsidiaries report....5 billion for the quarter ended September 30, 200...of last year. Operating income in the third quarte...e third quarter of last year. Net non-operating in...
(Date:11/6/2009)...,, CHARLESTON, S.C., Nov. 6 /PRNewswire-USNew... be stopping in South Carolina and Georgia through... order to help uninsured and financially-strugglin...vide prescription medicines for free or nearly fre... 10.2 percent, the Partnership for Prescription As...
(Date:11/6/2009)...,, SAN DIEGO, Nov. 6 ...company focused on developing products for minimal...nnounced today the appointment of Michael J. Lambe... Officer, effective November 9, 2009. The Company... Team updates. ,, "Michael will be an excellent...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 1Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 2Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 3Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 4Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 5Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 6Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 7Compirion and Anderson Surgery Center Reduce OR Inefficiencies and Improve Finances 53529 8PracticeMatch Announces Departure From Physician Recruiting 53526 1PracticeMatch Announces Departure From Physician Recruiting 53526 2Operation Rescue Announces Keep It Closed Campaign 53523 1Operation Rescue Announces Keep It Closed Campaign 53523 2
...hering-Plough,Corporation (NYSE: SGP ) today repo...senapine, a fast-dissolving, sublingual tablet bei...ore effective than placebo,and well tolerated in t...ding to the results, asenapine 5 mg twice daily an...ffective than placebo at improving,patient Positiv...
...SuperGen, Inc.,(Nasdaq: SUPG ) today announced th... multi-arm Phase 1b clinical trial of MP470, a nov...(TKI). The trial will evaluate,MP470 in combinatio...ens,including carboplatin/paclitaxel, carboplatin/... trial is expected to enroll up to 105,patients at...
Other Medicine Technology:New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 3New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 4SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor 2SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor 3
(Date:11/8/2009)..., WASHINGTON, Nov. 8 ...a press conference following the House passage of ...Act. The bill passed by a vote of 220 to 215. Be...nd some of my colleagues just received a call from... congratulating us on a great victory for the Amer...
(Date:11/8/2009)... Men’s Health Networ...ir health risks, especially those linked to exposu...rom military service. Bladder cancer is one of tho...erans, especially those who once smoked or current...shington DC (PRWEB) November 8, 2009 -- Men’...
(Date:11/8/2009)..., WASHINGTON, Nov. 7 ...dable Health Care for America Act, which will make...nsurance companies accountable and increase access...a public option. ,, "Teddy Roosevelt, FDR and H... Director Alan Charney. "Today,s vote ranks among ...
(Date:11/8/2009)..., Health Care Vote Shows Who Sides With Workin...RG, Pa., Nov. 8 On the ...of Representatives for a good, balanced health car...ts scoring of how our state,s U.S. representatives...America Act. ,, The legislation, which passed ...
(Date:11/7/2009)..., HOUSTON, Nov. 7, T...d its 2009 Benjamin Rush Award for Citizenship and...thalmologist from Chicago, IL. The award recognize...professional call of duty to make an outstanding p...y. Dr. Kraff received the award today during the o...
Breaking Medicine News(10 mins):Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2
...at the proposed Government plan to reduce the wait... be achieved without a substantial expansion of th...t in the health care facilities has also to be und...spread of sexually transmitted diseases. Dr. Helen...
...been warned of fines by the Government if it were ... services. Copeman Healthcare intends to establish... has announced that it will be charging a joining ...an be levied for every incident wherein charges ar...
...) patients, currently on a six-month waiting list ...ment report that would be released this Friday. //...at the maximum waiting period would not exceed six...Figures for November showed that more than 12, 300...
...atients afflicted by cancer, open heart surgeries,...everal others who are in need of blood platelet tr...at the University of British Columbia's Centre for...lood platelets are vital to promote clotting of bl...
...uter model has been developed that can predict the...ty whether it would be mild or severe can be told ... ample time for preventive or emergency measures t...sub-Saharan Africa. And it kills millions of peopl...
...ave revealed that they might have made a breakthro...anian devils. // These tumors spread by biting and...imals are mating, the researchers said. Devil ...the affected devil, "What we've shown, or we've sh...
Other Medicine News:Health News:Quality Platelets and Improved Blood Availability No Longer a Pipe Dream 2Health News:Prediction of malaria epidemics possible! 2
...medium designed for the direct detection and/or co...ted for the suppression of gram-negative organisms...eus hydrolyzes the chromogenic substrate resulting...n from other gram-positive organisms. A cephalospo...
Autoclavable Light Guides & Adapters
...h a 180 watt Xenon short arc lamp. Designed to pro... transfer from the lamp to the light guide, this l...alent to higher watt bulbs. A new IR filtering sys...mount of heat generated from the light source and ...
... your video equipment has led Linvatec to develop ...odate all of your multi-specialty video requiremen...ers in both traditional eyecup and proprietary fog...oom "C mount eyecup and both "C and "V mount eyecu...
Medicine Products: